AU2003294220A1 - Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES - Google Patents

Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Info

Publication number
AU2003294220A1
AU2003294220A1 AU2003294220A AU2003294220A AU2003294220A1 AU 2003294220 A1 AU2003294220 A1 AU 2003294220A1 AU 2003294220 A AU2003294220 A AU 2003294220A AU 2003294220 A AU2003294220 A AU 2003294220A AU 2003294220 A1 AU2003294220 A1 AU 2003294220A1
Authority
AU
Australia
Prior art keywords
key
antigenic epitope
peptide vaccines
hybrid peptide
epitope hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003294220A
Other languages
English (en)
Other versions
AU2003294220A8 (en
Inventor
Robert E. Humphreys
Minzhen Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/245,871 external-priority patent/US20030235594A1/en
Priority claimed from US10/253,286 external-priority patent/US7179645B2/en
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Publication of AU2003294220A1 publication Critical patent/AU2003294220A1/en
Publication of AU2003294220A8 publication Critical patent/AU2003294220A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003294220A 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES Abandoned AU2003294220A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/245,871 US20030235594A1 (en) 1999-09-14 2002-09-17 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/245,871 2002-09-17
US10/253,286 US7179645B2 (en) 2002-09-24 2002-09-24 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/253,286 2002-09-24
PCT/US2003/028574 WO2004030616A2 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Publications (2)

Publication Number Publication Date
AU2003294220A1 true AU2003294220A1 (en) 2004-04-23
AU2003294220A8 AU2003294220A8 (en) 2004-04-23

Family

ID=32072825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294220A Abandoned AU2003294220A1 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Country Status (5)

Country Link
EP (1) EP1556072B1 (enExample)
JP (1) JP2006515744A (enExample)
AU (1) AU2003294220A1 (enExample)
CA (1) CA2499123A1 (enExample)
WO (1) WO2004030616A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
JP5222134B2 (ja) * 2005-06-15 2013-06-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Ｈｅｒ−２ペプチド
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP2012050440A (ja) * 2011-09-16 2012-03-15 Chiba Univ ヒトＴｈ１／Ｔｈ２分化誘導の評価方法
PL2914286T3 (pl) * 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
KR20160075532A (ko) * 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
ES2983924T3 (es) * 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
CA3019266A1 (en) * 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
CN108129558B (zh) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
US20230000908A1 (en) * 2019-09-11 2023-01-05 Ohio State Innovation Foundation Engineered cells and uses thereof
WO2023240295A2 (en) * 2022-06-10 2023-12-14 Ayass Bioscience Llc Food allergen processing and desensitization by aptamers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DK0458841T3 (da) 1989-02-17 1995-11-20 Chiron Mimotopes Pty Ltd Fremgangsmåde til anvendelse og fremstilling af peptider
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
CA2067821A1 (en) 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
ATE176239T1 (de) 1990-11-21 1999-02-15 Iterex Pharma Lp Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5679527A (en) 1992-03-25 1997-10-21 Antigen Express, Inc. Modification of polypeptide structure
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
EP0800545B2 (en) 1995-11-01 2011-03-02 Bracco Research S.A. Targeted magnetically labeled molecular marker systems for the nmr imaging
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Also Published As

Publication number Publication date
EP1556072A4 (en) 2005-12-21
JP2006515744A (ja) 2006-06-08
AU2003294220A8 (en) 2004-04-23
EP1556072A2 (en) 2005-07-27
WO2004030616A3 (en) 2004-10-07
EP1556072B1 (en) 2010-05-19
WO2004030616A2 (en) 2004-04-15
CA2499123A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
GB2439474B (en) LI-Key/Antigenic epitope hybrid peptide vaccines
AU2003299535A1 (en) Group b streptococcus vaccine
AU2003270311A1 (en) Epitope sequences
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
AU2003294220A1 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
AU2001258279A1 (en) Adjuvant for vaccines
EP1572918A3 (en) Synthetic glyco-lipo-peptides as vaccines
EP1558628A4 (en) ANTIGENIC PEPTIDES
AU2003203002A1 (en) Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
AU2003228863A1 (en) Immunogenic peptides
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU2003283963A1 (en) Mage-c2 antigenic peptides and uses thereof
AU2001251394A1 (en) Immunological methodology for discerning human papillomavirus
WO2004058188A3 (en) Vaccine compositions and methods
AU2003221110A1 (en) Mucosal immune vaccine for periodontal diseases
AU2002365187A1 (en) Epitope synchronization in antigen presenting cells
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2003900767A0 (en) Idiotypic vaccine
AU2003276846A1 (en) Thrombopoiesis-stimulating proteins having reduced immunogenicity
AU2002303093A1 (en) Mycobacterial vaccines
GB0313064D0 (en) Mycobacterial vaccine
AU2001251250A1 (en) Neutralizing immunogenic HEV polypeptides
AU2003232739A1 (en) Ebv vaccine using gp350 antigen
AUPR975401A0 (en) Antigenic polypeptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase